Viridian Metals Inc

Viridian Therapeutics has entered into an exclusive licensing agreement with Kissei Pharmaceutical for veligrotug and VRDN-003 in Japan, receiving $70 million upfront with potential milestone payments up to $315 million.

• TEPEZZA, the first FDA-approved treatment for thyroid eye disease, generated $1.9 billion in sales for 2024, with $460 million in Q4 alone, addressing a critical unmet need for patients with limited treatment alternatives. • The global thyroid eye disease market reached $2.3 billion in 2023 across seven major markets, with continued growth expected through 2034 due to increasing disease awareness and rising prevalence. • Several competitors are developing alternative therapies, including Immunovant's batoclimab and Sling Therapeutics' oral small molecule linsitinib, potentially reshaping the treatment landscape in the coming years.

Viridian Therapeutics' veligrotug met all primary and secondary endpoints in the THRIVE-2 Phase 3 trial for chronic thyroid eye disease (TED).

Several companies are actively developing novel therapies for Graves' Disease, targeting mechanisms like IGF-1R and FcRn.

Viridian Therapeutics' veligrotug met primary and secondary endpoints in the THRIVE phase 3 trial for active thyroid eye disease (TED).

• Viridian Therapeutics' VRDN-001 (veligrotug) demonstrated satisfactory efficacy and safety in a Phase III THRIVE study for thyroid eye disease (TED). • The trial results suggest veligrotug could gain a moderate market share from Tepezza, with potential annual sales between $500 million and $700 million. • B.Riley increased Viridian's price target to $22.00, reflecting confidence in veligrotug's potential and the company's financial stability. • Viridian is advancing its TED treatments with ongoing Phase 3 trials for VRDN-001 and VRDN-003, supported by a strong cash position.

• Viridian Therapeutics' veligrotug met all primary and secondary endpoints in the Phase III THRIVE trial for active thyroid eye disease (TED). • The trial demonstrated statistically significant improvements in signs and symptoms of TED after 15 weeks of veligrotug treatment compared to placebo. • Veligrotug showed a rapid onset of action, with a favorable safety profile and no treatment-related serious adverse events reported. • Viridian plans to submit a biologics license application to the FDA in H2 2025, with topline data from the THRIVE-2 study expected by the end of this year.

• VRDN-001 demonstrates significant improvement in signs and symptoms of Thyroid Eye Disease (TED) after two infusions at 20 mg/kg, consistent with earlier 10 mg/kg results. • The Phase 1/2 trial data shows a 75% proptosis responder rate, a 75% overall responder rate, and a 75% complete resolution of diplopia across all VRDN-001 treated patients. • Viridian has initiated a global Phase 3 THRIVE clinical program for VRDN-001 in active TED, with topline data from a 3 mg/kg cohort expected in early January 2023. • VRDN-002, a novel subcutaneous formulation, shows a half-life of up to 43 days, supporting less frequent dosing, with proof-of-concept data expected in the second half of 2023.